The estimated Net Worth of Robert Chess is at least $4.1 Milhão dollars as of 14 June 2024. Mr. Chess owns over 19,500 units of Nektar Therapeutics stock worth over $319,091 and over the last 21 years he sold NKTR stock worth over $3,390,680. In addition, he makes $385,928 as Independent Chairman of the Board at Nektar Therapeutics.
Robert has made over 40 trades of the Nektar Therapeutics stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 19,500 units of NKTR stock worth $23,400 on 14 June 2024.
The largest trade he's ever made was exercising 29,500 units of Nektar Therapeutics stock on 29 December 2014 worth over $449,580. On average, Robert trades about 4,309 units every 53 days since 2003. As of 14 June 2024 he still owns at least 255,273 units of Nektar Therapeutics stock.
You can see the complete history of Mr. Chess stock trades at the bottom of the page.
Robert B. Chess serves as Independent Chairman of the Board of the Company. From March 2006 until January 2007, Mr. Chess served as our Acting President and Chief Executive Officer, and from April 1999 to January 2007, served as Executive Chairman. He also served as our Co-Chief Executive Officer from August 1998 to April 2000, as President from December 1991 to August 1998, and as Chief Executive Officer from May 1992 to August 1998. Mr. Chess was previously the co-founder and President of Penederm, Inc., a publicly-traded dermatological pharmaceutical company that was sold to Mylan Laboratories. He has held management positions at Intel Corporation and Metaphor Computer Systems (now part of IBM), and was a member of the first President Bush’s White House staff as a White House Fellow and Associate Director of the White House Office of Economic and Domestic Policy. From 1997 until his retirement in 2009, Mr. Chess served on the board of directors of the Biotechnology Industry Organization (“BIO”). Mr. Chess served as Chairman of BIO’s Emerging Companies Section and Co-Chairman of BIO’s Intellectual Property Committee. Mr. Chess was the initial Chairman of Bio Ventures for Global Health and continues to serve on its board. He also serves on the Board of Trustees of the California Institute of Technology where he chairs the Technology Transfer Committee. Mr. Chess is the co-founder and a member of the board of directors of Biota Technology, a private company developing applications of DNA-sequencing for the energy industry, and also serves on the board of directors and is a lead director of Twist Biosciences, a publicly-traded company in the synthetic DNA production field. He is currently a member of the faculty of the Stanford Graduate School of Business, where he teaches courses in the MBA program on starting technology-based businesses and the healthcare industry. Mr. Chess received his B.S. degree in Engineering with honors from the California Institute of Technology and an M.B.A. from Harvard University.
As the Independent Chairman of the Board of Nektar Therapeutics, the total compensation of Robert Chess at Nektar Therapeutics is $385,928. There are 11 executives at Nektar Therapeutics getting paid more, with Jonathan Zalevsky having the highest compensation of $39,242,200.
Robert Chess is 63, he's been the Independent Chairman of the Board of Nektar Therapeutics since 2007. There are 5 older and 12 younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin, 72, who is the Sr. VP of Clinical Devel. & Head of Immunology.
Robert's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO, CA, 94158.
Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie, eJohn Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Nektar Therapeutics executives and other stock owners filed with the SEC include: